ZA916905B - 1,2,5,6-tetrahydropyridine oxine derivatives - Google Patents

1,2,5,6-tetrahydropyridine oxine derivatives

Info

Publication number
ZA916905B
ZA916905B ZA916905A ZA916905A ZA916905B ZA 916905 B ZA916905 B ZA 916905B ZA 916905 A ZA916905 A ZA 916905A ZA 916905 A ZA916905 A ZA 916905A ZA 916905 B ZA916905 B ZA 916905B
Authority
ZA
South Africa
Prior art keywords
tetrahydropyridine
oxine derivatives
oxine
derivatives
tetrahydropyridine oxine
Prior art date
Application number
ZA916905A
Other languages
English (en)
Inventor
Steven Mark Bromidge
Mark Bromidge Steven
Barry Sidney Orlek
Sidney Orlek Barry
Steven Dabbs
Dabbs Steven
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of ZA916905B publication Critical patent/ZA916905B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA916905A 1990-09-01 1991-08-30 1,2,5,6-tetrahydropyridine oxine derivatives ZA916905B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019095A GB9019095D0 (en) 1990-09-01 1990-09-01 Novel compounds

Publications (1)

Publication Number Publication Date
ZA916905B true ZA916905B (en) 1992-08-26

Family

ID=10681500

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916905A ZA916905B (en) 1990-09-01 1991-08-30 1,2,5,6-tetrahydropyridine oxine derivatives

Country Status (10)

Country Link
US (1) US5314901A (fr)
EP (1) EP0546005A1 (fr)
JP (1) JPH06500325A (fr)
AU (1) AU8442791A (fr)
GB (1) GB9019095D0 (fr)
IE (1) IE913069A1 (fr)
MX (1) MX9100884A (fr)
PT (1) PT98824A (fr)
WO (1) WO1992004323A1 (fr)
ZA (1) ZA916905B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208343A (en) * 1992-03-24 1993-05-04 Warner-Lambert Company Tetrahydropyridine oxime compounds
EP2275096A3 (fr) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
WO2007047978A2 (fr) 2005-10-21 2007-04-26 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
EP2314289A1 (fr) 2005-10-31 2011-04-27 Braincells, Inc. Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (fr) 2006-09-08 2008-03-13 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA3058083A1 (fr) * 2017-04-27 2018-11-01 Basf Se Procede de preparation de composes 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium optiquement actifs
TWI797167B (zh) * 2018-09-28 2023-04-01 德商巴地斯顏料化工廠 用於製備光學活性嘧啶鎓化合物之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU563225B2 (en) * 1982-04-14 1987-07-02 Alizyme Therapeutics Limited I-aza bicyclic compounds
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
EP0261763B1 (fr) * 1986-06-27 1994-02-09 Beecham Group Plc Composés N-hétérocycliques bicycliques pontés
GB8615785D0 (en) * 1986-06-27 1986-08-06 Beecham Group Plc Compounds
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4798841A (en) * 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
ATE133415T1 (de) * 1987-04-15 1996-02-15 Beecham Group Plc Am brückenkopf substituierte azabicyclenderivate
IT1203971B (it) * 1987-04-24 1989-02-23 Roussel Maestretti Spa Derivati di 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro applicazione come medicamenti
IT1222526B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropiridin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IT1222529B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropirdin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
IT1233446B (it) * 1987-12-30 1992-04-01 Roussel Maestretti Spa Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
US5110828A (en) * 1988-04-15 1992-05-05 Beecham Group P.L.C. Azabicyclo oxime derivatives
IT1227436B (it) * 1988-10-28 1991-04-11 Roussel Maestretti Spa Derivati di 1-azabicicloalcani, loro procedimento di preparazione e loro applicazione come farmaci
US4937239A (en) * 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
ATE269330T1 (de) * 1989-04-13 2004-07-15 Beecham Group Plc Chemische verbindungen

Also Published As

Publication number Publication date
PT98824A (pt) 1992-07-31
EP0546005A1 (fr) 1993-06-16
JPH06500325A (ja) 1994-01-13
WO1992004323A1 (fr) 1992-03-19
AU8442791A (en) 1992-03-30
MX9100884A (es) 1992-05-04
GB9019095D0 (en) 1990-10-17
IE913069A1 (en) 1992-03-11
US5314901A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
AU660321B2 (en) 1,2-dihydro-2-oxopyridine
EP0569493A4 (en) Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
ZA916058B (en) Novel 1,4-dihydropyridine derivatives
GB2260135B (en) Substituted 2,6-diaminotoluenes
AU8442791A (en) 1,2,5,6-tetrahydropyridine oxime derivatives
HU9302314D0 (en) 1,4-benzodioxane derivatives
EP0391187A3 (en) Substituted 4-amino-5-alkylthio-1,2,4-triazol-3-ones
EP0474129A3 (en) 1,4-dihydropyridine derivatives and process for preparing the same
EP0481950A3 (en) 1,4-dideoxy-4-fluoronojirimycin
EP0482206A4 (en) 4,6-o-hydroxyphosphorylglucosamine derivative
HU908313D0 (en) New 15-nitro-2betha, 3betha-dihydro- and 15-nitro-2betha, 3 betha,6,7-tetrahydro-tabersonine derivatives
HU9301651D0 (en) Pyridyl-1,2,5-oxadiazole-carbonamide-2-oxide derivatives
ZA90301B (en) 8,9-annelated-1,2,3,4-tetrahydro-beta-carboline derivatives
ZA925184B (en) 3,4-dehydropiperidine derivatives
HU210820A9 (en) 1,2,3,6-tetrahydropyridine derivatives
GB8906324D0 (en) 1,4-dihydropyridines
HU908254D0 (en) New piperidine- and 1,2,3,6-tetrahydro-pyridine derivatives
ZA918076B (en) 1,2,5,6-tetrahydropyridine oxime derivatives
HU9402902D0 (en) 1,2-dihydro-2-oxo-3-methyl-sulfonyl-aminomethyl-pyridine derivatives
IE901509L (en) 1,5-benzothiazepin derivatives
EP0444276A3 (en) 1,2,4-triazolyl-propanol derivatives
IE900167L (en) 8,9-ANNELATED-1,2,3,4-TETRAHYDRO-ß-CARBOLINE DERIVATIVES
GB2266530B (en) Substituted 1,1,2-triphenylbutenes
IE900875L (en) 1,4-dihydro-4-oxo-naphthyridine-3-carboxylate
IE902043L (en) 2,5-diaryltetrahydrofurans